4Graul A, Rabasseda X, Castaner J. T-3811 ME [ J ]. Drugs Future,1999,24(12) :1324
5Gordon KA, Pfaller MA, Jones RN, et al. BMS-284756 ( formerly T-3811, a des-fluoroquinolone)potency and spectrum tested against over 10000 bacterial bloodstream infection isolates from the SENTRY antimierobial surveillance programme(2000) [ J ]. J Antimicrob Chemother ,2002,49 ( 5 ) : 851
6Rolston KV, Frisbee-hume S, LeBlanc BM, et al. Anitimicrobial activity of a noval des-fluoro ( 6 ) quinolone, garenoxacin ( BMS-254756), compared to other quinolones, against clinical isolates from cancer patients [ J ]. Diagn Microbiol Infect Dis,2002,44(2) :187
7Fung-tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro ( 6 ) quinolone, BMS-284756[ J ]. Antimicrob Agents Chemother,2000,44 ( 12 ) :3351
8Liebetrau A, Rod.loft AC ,Behra-Miellet J ,et al. In vitro activities of a new des-fluoro (6) quioolone, garenoxacin, against clinical anaerobic bacteria [ J ]. Antimicrob Agents Chemother,2003,47 ( 11 ) :3667
9Pereyre S, Renaudin H, Bebear C, et al. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas [J]. Antimicrob Agents Chemother,2004,48 ( 8 ) : 3165
10Kappel EM, Shakibaei M, Bello A, et al. Effects of the desfluoro (6) quinolone garonoxacin ( BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats [ J ]. Antimicrob Agents Chemother,2002,46(10) :3320
二级参考文献13
1Bassetti M, Dembry LM, Farrel PA, et al. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and β-1actams against gram- positive clinical isolates [J]. Antimicrob Agents Chemother,2002,46( 1 ) :234
2Ellie JCG, Diane MC, Vreni CM, et al. In vitro activities of the des-fluoro ( 6 ) -quinolone, BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections [ J ]. Antimicrob Agents Chemother ,2002 , 46 (3) :866
3Takahata M,Mitsuyama J,Yamashiko Y,et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des fluoro ( 6 )-quinolone [ J ]. Antimicrob Agents Chemother,1999,43(5) :1077
4Azoulay-Dupuis E, Bedos JP, Mohler J, et al. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model [ J ]. Antimicrob Agents Chemother,2004,48 ( 3 ) :765
5Rodriguez-Cerrato V, McCoig CC, Saavedra J, et al. Garenoxacin (BMS-284756) and moxifloxacin in vexperimental meningitis caused by vancomycin-tolerant pneumococci [ J ].Antimicrob Agents Chemother,2003, 47( 1 ) :211
6Pankuch GA, Jacobs MR, Appelbaum PC. Postanibiotic effects of garenoxacin(BMS-284756) against 12 gram-positive or-negative organisma [ J ]. Antimicrob Agents Chemother,2003,47 (3): 1140
7Entenza JM, Vouillamoz J, Glauser MP, et al. Effects of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci [ J ]. Antimicrob Agents Chemother,2004,48( 1 ) :86
8Akahata M,Mitsuyama J,Yamashiko Y,et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae [ J ]. Antimicrob Agents Chemother,2001,45(1) :312
9Ken BW, Donna MC, Xue B, et al. In vitro susceptibilities to and bactericidal activities of garenoxacin(BMS-284756)and other antimicrobial agents against human Mycoplasmas and Ureaplasmas [ J ]. Antimicrob Agents Chemother , 2003,47( 1 ) :161
10Malay S,Patricia MR,Tamara R,et al. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae [ J ]. Antimicrob Agents Chemother,2002,46 (2) :517
